Skip Navigation

European Journal of Heart Failure 2001 3(2):155-163; doi:10.1016/S1388-9842(00)00148-3
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Caforio, A. L.P.
Right arrow Articles by McKenna, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caforio, A. L.P.
Right arrow Articles by McKenna, W. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2001 European Society of Cardiology

Elevated serum levels of soluble interleukin-2 receptor, neopterin and β-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesis

Alida L.P. Caforioa,b,*, Jonathan H. Goldmanb, Mirza K. Baigb, Niall J. Mahonb, Aldwyn J. Havenb, Bernard E. Souberbiellec, David W. Holtb,d, Angus G. Dalgleishc and William J. McKennab

a Division of Cardiology, Department of Clinical and Experimental Medicine, University of Padua Padua, Italy
b Department of Cardiological Sciences, St George's Hospital Medical School London, England, UK
c Department of Oncology, St George's Hospital Medical School London, England, UK
d Analytical Unit, St George's Hospital Medical School London, England, UK

* Corresponding author. Division of Cardiology, Department of Experimental and Clinical Medicine, University of Padua, Policlinico universitario, Centro ‘V. Gallucci’, Via N. Giustiniani, 2, 35128 Padova, Italy. Tel.: +39-049-8212348; fax: +39-049-8754179. E-mail address: acaforio{at}ux1.unipd.it (A.L. Caforio).


   Abstract

Background: It has not been assessed whether high levels of soluble interleukin 2 receptor (sIL-2R), neopterin and β-2 microglobulin in idiopathic dilated cardiomyopathy reflect heart failure severity and/or an active autoimmune process. The aim of this study was to relate serum levels of these markers to clinical and autoimmune features.

Methods: We studied 60 patients with idiopathic dilated cardiomyopathy, 67 controls with ischemic heart failure and 34 normals.

Results: Abnormal levels of sIL-2R, but not of neopterin and β-2 microglobulin, were more frequent in idiopathic dilated cardiomyopathy than in ischemic patients (35% vs. 16%; P = 0.02) or in normals (35% vs. 12%, P = 0.01); mean sIL-2R levels were, however, similar in idiopathic dilated cardiomyopathy and ischemic heart failure (842 ± 75 vs. 762 ± 93 U/ml, P = NS). In idiopathic dilated cardiomyopathy abnormal levels of sIL-2R were associated with lower peak oxygen consumption (P = 0.008), higher neopterin and HLA class II expression in the myocardium (P = 0.02), but were unrelated to cardiac autoantibody status or titer. In addition, abnormal levels of neopterin were associated with adverse prognosis and higher β-2 microglobulin; abnormal levels of β-2 microglobulin with lower echocardiographic percent fractional shortening, higher sIL-2R and higher neopterin.

Conclusions: There is no convincing evidence that abnormal sIL-2R, neopterin and/or β-2 microglobulin are disease-specific markers of idiopathic dilated cardiomyopathy. The lack of association with cardiac autoantibodies suggests that these abnormalities are mainly related to heart failure severity rather than autoimmune pathogenesis. In keeping with this view, high levels of sIL-2R, neopterin and/or β-2 microglobulin identified a subset of idiopathic dilated cardiomyopathy patients with advanced disease and poor prognosis.

Key Words: Dilated cardiomyopathy • Cellular immunity • Heart failure

Received October 11, 2000; Revised October 27, 2000; Accepted November 30, 2000


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
ANGIOLOGYHome page
J. Barani, I. Mattiasson, B. Lindblad, and A. Gottsater
Cardiac Function, Inflammatory Mediators and Mortality in Critical Limb Ischemia
Angiology, August 1, 2006; 57(4): 437 - 444.
[Abstract] [PDF]


Home page
Clin. Chem.Home page
S. A. Jortani, S. D. Prabhu, and R. Valdes Jr
Strategies for Developing Biomarkers of Heart Failure
Clin. Chem., February 1, 2004; 50(2): 265 - 278.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Schroecksnadel, B. Wirleitner, D. Fuchs, W. Steinborn, P. Ponikowski, S. Anker, P. van der Meer, W. H. van Gilst, D. J. van Veldhuisen, J. Ezekowitz, et al.
Anemia and Congestive Heart Failure * Response
Circulation, August 12, 2003; 108 (6): e41 - e42.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
A. L.P. Caforio, N. J. Mahon, F. Tona, and W. J. McKenna
Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance
Eur J Heart Fail, August 1, 2002; 4(4): 411 - 417.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.